David Earp

David J. Earp is the President and CEO of Circle Pharma, a South San Francisco clinical-stage biopharmaceutical company building orally available macrocycle drugs aimed at cancer targets long deemed undruggable. A biochemist turned patent lawyer turned chief executive, Earp holds a PhD in biochemistry from Cambridge and a JD from Lewis & Clark, and has led Circle since 2013, steering it through a $90M Series D, a $607M collaboration with Boehringer Ingelheim, and the first human dosing of its lead cyclin A/B inhibitor CID-078.